ValuEngine Lowers Novo Nordisk A/S (NYSE:NVO) to Strong Sell

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Tuesday, ValuEngine reports.

A number of other equities analysts have also commented on the stock. Pareto Securities lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Citigroup raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group lowered shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, November 18th. Finally, Barclays raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $159.65.

Novo Nordisk A/S stock opened at $56.02 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.00 and a quick ratio of 0.73. Novo Nordisk A/S has a 1-year low of $43.60 and a 1-year high of $58.01. The firm has a market capitalization of $132.96 billion, a P/E ratio of 22.23, a price-to-earnings-growth ratio of 2.26 and a beta of 0.61. The company’s 50-day moving average is $55.25 and its 200 day moving average is $51.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The company had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. Research analysts anticipate that Novo Nordisk A/S will post 2.45 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Advisors Preferred LLC purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $26,000. Winthrop Partners WNY LLC bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $28,000. Prime Capital Investment Advisors LLC bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $28,000. Wealthcare Advisory Partners LLC boosted its stake in shares of Novo Nordisk A/S by 75.6% during the second quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock valued at $44,000 after purchasing an additional 372 shares in the last quarter. Finally, Mirova bought a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $49,000. 7.32% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: Why is the LIBOR significant?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.